Last reviewed · How we verify
MTL-CEBPA
At a glance
| Generic name | MTL-CEBPA |
|---|---|
| Sponsor | Mina Alpha Limited |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Phase I Study of RNA Oligonucleotide, MTL-CEBPA, Atezolizumab and Bevacizumab in Patients With Advanced Hepatocellular Carcinoma. (PHASE1)
- First-in-Human Safety, Tolerability and Antitumour Activity Study of MTL-CEBPA in Patients With Advanced Liver Cancer (PHASE1)
- A Study of MTL-CEBPA in Combination With a PD-1 Inhibitor in Patients With Advanced Solid Tumours (TIMEPOINT) (PHASE1)
- Radomised Phase II Study of MTL-CEBPA Plus Sorafenib or Sorafenib Alone (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MTL-CEBPA CI brief — competitive landscape report
- MTL-CEBPA updates RSS · CI watch RSS
- Mina Alpha Limited portfolio CI